blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3127921

EP3127921 - METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITION IN CDR [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  14.09.2018
Database last updated on 24.04.2024
FormerRequest for examination was made
Status updated on  04.08.2017
FormerThe application has been published
Status updated on  06.01.2017
Most recent event   Tooltip26.03.2024New entry: Decision on request for further processing 
Applicant(s)For all designated states
CHUGAI SEIYAKU KABUSHIKI KAISHA
5-1, Ukima 5-chome
Kita-ku
Tokyo 115-8543 / JP
[2017/06]
Inventor(s)01 / IGAWA, Tomoyuki
c/o Chugai Seiyaku Kabushiki Kaisha
135 Komakado 1-chome
Gotenba-shi, Shizuoka, 412-8513 / JP
02 / TSUNODA, Hiroyuki
c/o Chugai Seiyaku Kabushiki Kaisha
135 Komakado 1-chome
Gotenba-shi, Shizuoka, 412-8513 / JP
03 / TACHIBANA, Tatsuhiko
c/o Chugai Seiyaku Kabushiki Kaisha
135 Komakado 1-chome
Gotenba-shi, Shizuoka, 412-8513 / JP
04 / KURAMOCHI, Taichi
c/o Chugai Seiyaku Kabushiki
135 Komakado 1-chome
Gotenba-shi, Shizuoka, 412-8513 / JP
 [2017/06]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2017/06]
Application number, filing date16183476.726.09.2008
[2017/06]
Priority number, dateJP2007025016526.09.2007         Original published format: JP 2007250165
JP2007025606328.09.2007         Original published format: JP 2007256063
[2017/06]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3127921
Date:08.02.2017
Language:EN
[2017/06]
Search report(s)(Supplementary) European search report - dispatched on:EP21.12.2016
ClassificationIPC:C07K16/28, A61K39/395, A61P43/00, C07K16/46, C12N1/15, C12N1/19, C12N1/21, C12N5/10, C12N15/09, C12P21/02
[2017/06]
CPC:
A61K39/39591 (EP,CN,IL,US); C07K16/28 (EP,IL,KR,US); C07K16/00 (EP,CN,IL,US);
C07K16/2866 (EP,IL,US); A61K39/39 (KR); A61P37/02 (EP);
A61P43/00 (EP); C07K1/16 (KR); C12N15/63 (KR);
G01N33/6854 (IL,US); C07K2317/24 (IL,US); C07K2317/565 (EP,CN,IL,US);
C07K2317/732 (EP,CN,IL,US); C07K2317/94 (CN) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/36]
Former [2017/06]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:VERFAHREN ZUR MODIFIZIERUNG EINES ISOELEKTRISCHEN PUNKTS EINES ANTIKÖRPERS ÜBER AMINOSÄURESUBSTITION IN CDR[2017/06]
English:METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITION IN CDR[2017/06]
French:PROCÉDÉ DE MODIFICATION D'UN ANTICORPS PAR POINT ISOÉLECTRIQUE PAR SUBSTITUTION D'ACIDE AMINÉ DANS CDR[2017/06]
Examination procedure10.08.2016Date on which the examining division has become responsible
27.07.2017Examination requested  [2017/36]
21.11.2017Amendment by applicant (claims and/or description)
12.09.2018Despatch of a communication from the examining division (Time limit: M06)
28.06.2019Reply to a communication from the examining division
03.06.2020Despatch of a communication from the examining division (Time limit: M08)
19.05.2021Reply to a communication from the examining division
15.06.2023Despatch of a communication from the examining division (Time limit: M06)
24.01.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
19.03.2024Reply to a communication from the examining division
Parent application(s)   TooltipEP08834150.8  / EP2202245
Divisional application(s)EP20159129.4  / EP3689912
EP24152321.6
EP24152324.0  / EP4339294
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
19.03.2024Request for further processing filed
19.03.2024Full payment received (date of receipt of payment)
Request granted
25.03.2024Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
19.05.2021Request for further processing filed
19.05.2021Full payment received (date of receipt of payment)
Request granted
31.05.2021Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
28.06.2019Request for further processing filed
28.06.2019Full payment received (date of receipt of payment)
Request granted
08.07.2019Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
21.11.2017Request for further processing filed
21.11.2017Full payment received (date of receipt of payment)
Request granted
30.11.2017Decision despatched
Fees paidRenewal fee
07.12.2016Renewal fee patent year 03
07.12.2016Renewal fee patent year 04
07.12.2016Renewal fee patent year 05
07.12.2016Renewal fee patent year 06
07.12.2016Renewal fee patent year 07
07.12.2016Renewal fee patent year 08
07.12.2016Renewal fee patent year 09
22.09.2017Renewal fee patent year 10
24.09.2018Renewal fee patent year 11
24.09.2019Renewal fee patent year 12
23.09.2020Renewal fee patent year 13
23.09.2021Renewal fee patent year 14
20.09.2022Renewal fee patent year 15
21.09.2023Renewal fee patent year 16
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO9803546  (AMGEN INC [US], et al) [A] 1-15 * page 2, line 33 - line 35 * * page 21, line 25 - line 30 * * page 26, line 5 - line 10 * * page 1; table 2 * * page 36 *;
 [X]WO2006004663  (MEDIMMUNE INC [US], et al) [X] 13-15 * figure 1B *;
 [A]US2007059312  (BACA MANUEL [AU], et al) [A] 1-15 * table 11 *;
 [AP]WO2007114319  (CHUGAI PHARMACEUTICAL CO LTD [JP], et al) [AP] 1-15 * the whole document *;
 EP2006381  [ ] (CHUGAI PHARMACEUTICAL CO LTD [JP]) [ ] * paragraph [0005] * * paragraph [0009] * * paragraph [0020] * * paragraph [0022] * * page 5, lines 10,19 *;
 [A]  - TAN P H ET AL, "Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL LNKD- DOI:10.1016/S1380-2933(98)00011-6, (19981001), vol. 4, no. 2, ISSN 1380-2933, pages 107 - 114, XP004153635 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1016/S1380-2933(98)00011-6
by applicantEP0125023
 EP0239400
 EP0404097
 WO9201047
 WO9203918
 WO9220791
 JPH059878B
 WO9306213
 WO9311161
 WO9311236
 WO9312227
 WO9319172
 WO9402602
 WO9501438
 WO9515393
 WO9515388
 WO9602576
 WO9634096
 WO9633735
 WO9813388
 WO9846777
 WO03039485
 US2006019342
 WO2006046751
 US2006122377
 US2006194280
 WO2007014278
 WO2007059782
 WO2007114319
 WO2007114325
 US2007280945
 JP2008504970
    - JANICE M REICHERT; CLARK J ROSENSWEIG; LAURA B FADEN; MATTHEW C DEWITZ, "Monoclonal antibody successes in the clinic", NATURE BIOTECHNOLOGY, (2005), vol. 23, doi:doi:10.1038/nbt0905-1073, pages 1073 - 1078, XP002555770

DOI:   http://dx.doi.org/10.1038/nbt0905-1073
    - PAVLOU AK; BELSEY MJ., "The therapeutic antibodies market to 2008", EUR J PHARM BIOPHARM, (200504), vol. 59, no. 3, doi:doi:10.1016/j.ejpb.2004.11.007, pages 389 - 96, XP025317626

DOI:   http://dx.doi.org/10.1016/j.ejpb.2004.11.007
    - PRESTA LG, "Engineering of therapeutic antibodies to minimize immunogenicity and optimize function", ADV DRUG DELIV REV., (20060807), vol. 58, no. 5-6, doi:doi:10.1016/j.addr.2006.01.026, pages 640 - 56, XP024892146

DOI:   http://dx.doi.org/10.1016/j.addr.2006.01.026
    - KIM SJ; PARK Y; HONG HJ, "Antibody engineering for the development of therapeutic antibodies", MOL CELLS., (20050831), vol. 20, no. 1, pages 17 - 29, XP055199890
    - FUJII I, "Antibody affinity maturation by random mutagenesis", METHODS MOL BIOL, (2004), vol. 248, pages 345 - 59
    - SHIRE SJ; SHAHROKH Z; LIU J, "Challenges in the development of high protein concentration formulations", J PHARM SCI., (200406), vol. 93, no. 6, doi:doi:10.1002/jps.20079, pages 1390 - 402, XP009108986

DOI:   http://dx.doi.org/10.1002/jps.20079
    - SALFELD JG., "Isotype selection in antibody engineering", NAT BIOTECHNOL., (200712), vol. 25, no. 12, doi:doi:10.1038/nbt1207-1369, pages 1369 - 72, XP002668461

DOI:   http://dx.doi.org/10.1038/nbt1207-1369
    - HINTON PR; JOHLFS MG; XIONG JM; HANESTAD K; ONG KC; BULLOCK C; KELLER S; TANG MT; TSO JY; VASQUEZ M, "Engineered human IgG antibodies with longer serum half-lives in primates", J BIOL CHEM., (20040220), vol. 279, no. 8, pages 6213 - 6
    - HINTON PR; XIONG JM; JOHLFS MG; TANG MT; KELLER S; TSURUSHITA N, "An engineered human IgGI antibody with longer serum half-life", J IMMUNOL., (20060101), vol. 176, no. L, pages 346 - 56
    - GHETIE V; POPOV S; BORVAK J; RADU C; MATESOI D; MEDESAN C; OBER RJ; WARD ES., "Increasing the serum persistence of an IgG fragment by random mutagenesis", NAT BIOTECHNOL., (199707), vol. 15, no. 7, doi:doi:10.1038/nbt0797-637, pages 637 - 40, XP000876642

DOI:   http://dx.doi.org/10.1038/nbt0797-637
    - ALMAGRO JC; FRANSSON J., "Humanization of antibodies", FRONT BIOSCI., (20080101), vol. 13, pages 1619 - 33
    - LIU H; GAZA-BULSECO G; FALDU D; CHUMSAE C; SUN J., "Heterogeneity of monoclonal antibodies", J PHARM SCI., (200807), vol. 97, no. 7, pages 2426 - 47
    - CHEN C; ROBERTS VA; RITTENBERG MB, "Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen", J EXP MED., (19920901), vol. 176, no. 3, doi:doi:10.1084/jem.176.3.855, pages 855 - 66, XP002517166

DOI:   http://dx.doi.org/10.1084/jem.176.3.855
    - CHEN C; MARTIN TM; STEVENS S; RITTENBERG MB., "Defective secretion of an immunoglobulin caused by mutations in the heavy chain complementarity determining region 2.", J EXP MED., (19940801), vol. 180, no. 2, pages 577 - 86
    - WIENS GD; HELDWEIN KA; STENZEL-POORE MP; RITTENBERG MB., "Somatic mutation in VH complementarity-determining region 2 and framework region 2: differential effects on antigen binding and Ig secretion.", J IMMUNOL., (19970801), vol. 159, no. 3, pages 1293 - 302
    - WIENS GD; LEKKERKERKER A; VELTMAN I; RITTENBERG MB, "Mutation of a single conserved residue in VH complementarity-determining region 2 results in a severe Ig secretion defect", J IMMUNOL., (20010815), vol. 167, no. 4, pages 2179 - 86
    - ZWICK MB; KOMORI HK; STANFIELD RL; CHURCH S; WANG M; PARREN PW; KUNERT R; KATINGER H; WILSON IA; BURTON DR, "The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5.", J VIROL, (200403), vol. 78, no. 6, doi:doi:10.1128/JVI.78.6.3155-3161.2004, pages 3155 - 61, XP008125658

DOI:   http://dx.doi.org/10.1128/JVI.78.6.3155-3161.2004
    - KOMISSAROV AA; MARCHBANK MT; CALCUTT MJ; QUINN TP; DEUTSCHER SL, "Site-specific mutagenesis of a recombinant anti-single-stranded DNA Fab. Role of heavy chain complementarity-determining region 3 residues in antigen interaction", J BIOL CHEM., (19971024), vol. 272, no. 43, pages 26864 - 70
    - GERSTNER RB; CARTER P; LOWMAN HB, "Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody", J MOL BIOL., (20020830), vol. 321, no. 5, doi:doi:10.1016/S0022-2836(02)00677-0, pages 851 - 62, XP002972421

DOI:   http://dx.doi.org/10.1016/S0022-2836(02)00677-0
    - VAJDOS FF; ADAMS CW; BREECE TN; PRESTA LG; DE VOS AM; SIDHU SS, "Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis", J MOL BIOL., (20020705), vol. 320, no. 2, doi:doi:10.1016/S0022-2836(02)00264-4, pages 415 - 28, XP027251270

DOI:   http://dx.doi.org/10.1016/S0022-2836(02)00264-4
    - PONS J; RAJPAL A; KIRSCH JF, "Energetic analysis of an antigen/antibody interface: alanine scanning mutagenesis and double mutant cycles on the HyHEL-10/lysozyme interaction", POTEIN SCI., (199905), vol. 8, no. 5, doi:doi:10.1110/ps.8.5.958, pages 958 - 68, XP002521752

DOI:   http://dx.doi.org/10.1110/ps.8.5.958
    - LEONG SR; DEFORGE L; PRESTA L; GONZALEZ T; FAN A; REICHERT M; CHUNTHARAPAI A; KIM KJ; TUMAS DB; LEE WP, "Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation", CYTOKINE, (20011107), vol. 16, no. 3, doi:doi:10.1006/cyto.2001.0936, pages 106 - 19, XP002665741

DOI:   http://dx.doi.org/10.1006/cyto.2001.0936
    - XIANG J; SRIVAMADAN M; RAJALA R; JIA Z, "Study of B72.3 combining sites by molecular modeling and site-directed mutagenesis", PROTEIN ENG., (200005), vol. 13, no. 5, pages 339 - 44
    - ROTHE A; HOSSE RJ; POWER BE, "Ribosome display for improved biotherapeutic molecules", EXPERT OPIN BIOL THER, (200602), vol. 6, no. 2, doi:doi:10.1517/14712598.6.2.177, pages 177 - 87, XP009105147

DOI:   http://dx.doi.org/10.1517/14712598.6.2.177
    - SCHMITZ U; VERSMOLD A; KAUFMANN P; FRANK HG, "Phage display: a molecular tool for the generation of antibodies--a review", PLACENTA, (200003), vol. 21, pages 106 - 12
    - RAJPAL A; BEYAZ N; HABER L; CAPPUCCILLI G; YEE H; BHATT RR; TAKEUCHI T; LERNER RA; CREA R, "A general method for greatly improving the affinity of antibodies by using combinatorial libraries", PROC NATL ACAD SCI USA., (20050614), vol. 102, no. 24, doi:doi:10.1073/pnas.0503543102, pages 8466 - 71, XP002392777

DOI:   http://dx.doi.org/10.1073/pnas.0503543102
    - DE GROOT AS; KNOPP PM; MARTIN W, "De-immunization of therapeutic proteins by T-cell epitope modification", DEV BIOL (BASEL, (2005), vol. 122, pages 171 - 94, XP008074262
    - NYGREN ET AL., CURRENT OPINION IN STRUCTURAL BIOLOGY, (1997), vol. 7, pages 463 - 469
    - JOURNAL OF IMMUNOL METHODS, (2004), vol. 290, pages 3 - 28
    - BINZ ET AL., NATURE BIOTECH, (2005), vol. 23, pages 1257 - 1266
    - HOSSE ET AL., PROTEIN SCIENCE, (2006), vol. 15, pages 14 - 27
    - ORITA ET AL., BLOOD, (2005), vol. 105, pages 562 - 566
    - HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 83
    - PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, SPRINGER VERLAG, (1994), vol. 113, pages 269 - 315
    - HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 8
    - JOHNSON ET AL., METHOD IN ENZYMOLOGY, (1991), vol. 203, pages 88 - 98
    - HOLLIGER ET AL., PROTEIN ENGINEERING, (1996), vol. 9, pages 299 - 305
    - PERISIC ET AL., STRUCTURE, (1994), vol. 2, pages 1217 - 26
    - JOHN ET AL., PROTEIN ENGINEERING, (1999), vol. 12, no. 7, pages 597 - 604
    - ATWELL ET AL., MOL. IMMUNOL., (1996), vol. 33, pages 1301 - 12
    - HUDSON ET AL., J IMMUNOL. METHODS, (1999), vol. 231, pages 177 - 89
    - JOURNAL OF IMMUNOLOGICAL METHODS, (1999), vol. 231, pages 177 - 89
    - CANCER RESEARCH, (2000), vol. 60, pages 4336 - 41
    - MORIMOTO ET AL., J. BIOCHEM. BIOPHYS. METHODS, (1992), vol. 24, pages 107 - 17
    - BRENNAN ET AL., SCIENCE, (1985), vol. 229, page 81
    - CO ET AL., J. IMMUNOL., (1994), vol. 152, pages 2968 - 76
    - BETTER; HORWITZ, METHODS ENZYMOL., (1989), vol. 178, pages 476 - 96
    - PLUCKTHUN; SKERRA, METHODS ENZYMOL., (1989), vol. 178, pages 497 - 515
    - LAMOYI, METHODS ENZYMOL., (1986), vol. 121, pages 652 - 63
    - ROUSSEAUX ET AL., METHODS ENZYMOL., (1986), vol. 121, pages 663 - 9
    - BIRD; WALKER, TRENDS BIOTECHNOL., (1991), vol. 9, pages 132 - 7
    - PLUCKTHUN, The Pharmacology of Monoclonal Antibody, SPRINGER VERLAG, (1994), vol. 113, pages 269 - 315
    - P. HOLLIGER ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
    - HE XY; XU Z; MELROSE J; MULLOWNEY A; VASQUEZ M; QUEEN C; VEXLER V; KLINGBEIL C; CO MS; BERG EL, "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin", J IMMUNOL., (1998), vol. 160, no. 2, pages 1029 - 35, XP002959848
    - J IMMUNOL., (1998), vol. 160, no. 2, pages 1029 - 35
    - BINZ HK; AMSTUTZ P; PLUCKTHUN A, "Engineering novel binding proteins from nonimmunoglobulin domains.", NAT BIOTECHNOL., (200510), vol. 23, no. 10, doi:doi:10.1038/nbt1127, pages 1257 - 68, XP002381839

DOI:   http://dx.doi.org/10.1038/nbt1127
    - KATAYOSE Y; KUDO T; SUZUKI M; SHINODA M; SAIJYO S; SAKURAI N; SAEKI H; FUKUHARA K; IMAI K; MATSUNO S, "MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth", CANCER RES., (1996), vol. 56, no. 18, pages 4205 - 12, XP002932515
    - CURR. OPIN. DRUG DISCOV. DEVEL., (2006), vol. 9, no. 2, pages 184 - 93
    - ONO K; OHTOMO T; YOSHIDA K; YOSHIMURA Y; KAWAI S; KOISHIHARA Y; OZAKI S; KOSAKA M; TSUCHIYA M., "The humanized a-,it.-HMIJ.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity", MOL. IMMUNOL., (1999), vol. 36, no. 6, doi:doi:10.1016/S0161-5890(99)00029-2, pages 387 - 395, XP002282626

DOI:   http://dx.doi.org/10.1016/S0161-5890(99)00029-2
    - DALL'ACQUA WF; DAMSCHRODER MM; ZHANG J; WOODS RM; WIDJAJA L; YU J; WU H, "Antibody humanization by framework shuffling", METHODS, (2005), vol. 36, no. 1, doi:doi:10.1016/j.ymeth.2005.01.005, pages 43 - 60, XP004852552

DOI:   http://dx.doi.org/10.1016/j.ymeth.2005.01.005
    - GOBBURU JV; TENHOOR C; ROGGE MC; FRAZIER DE JR; THOMAS D; BENJAMIN C; HESS DM; JUSKO WJ., "Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD 154 (CD40 ligand) suppression of an immune response in monkeys", J PHARMACOL EXP THER, (1998), vol. 286, no. 2, pages 925 - 30, XP000989582
    - KASHMIRI SV; SHU L; PADLAN EA; MILENIC DE; SCHLOM J; HAND PH, "Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49", HYBRIDOMA, (1995), vol. 14, no. 5, pages 461 - 73, XP000198397
    - GRAVES SS; GOSHORN SC; STONE DM; AXWORTHY DB; RENO JM; BOTTINO B; SEARLE S; HENRY A; PEDERSEN J; REES AR, "Molecular modeling and preclinical evaluation of the humanized NR-LU-13 antibody", CLIN CANCER RES., (1999), vol. 5, no. 4, pages 899 - 908, XP000941615
    - COUTO JR; BLANK EW; PETERSON JA; CERIANI RL, "Anti-BA46 monoclonal antibody Mc3: humanization using a novel positional consensus and in vivo and in vitro characterization", CANCER RES., (1995), vol. 55, no. 8, pages 1717 - 22, XP000919432
    - NAT BIOTECHNOL., (1997), vol. 15, no. 7, pages 637 - 40
    - ADAMS CW; ALLISON DE; FLAGELLA K; PRESTA L; CLARKE J; DYBDAL N; MCKEEVER K; SLIWKOWSKI MX, "Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab", CANCER IMMUNOL IMMUNOTHER., (2006), vol. 55, no. 6, doi:doi:10.1007/s00262-005-0058-x, pages 717 - 27, XP019333247

DOI:   http://dx.doi.org/10.1007/s00262-005-0058-x
    - VAISITTI T; DEAGLIO S; MALAVASI F, "Cationization of monoclonal antibodies: another step towards the ''magic bullet''?", J BIOL REGUL HOMEOSTAGENTS., (2005), vol. 19, no. 3-4, pages 105 - 12, XP009125963
    - PARDRIDGE WM; BUCIAK J; YANG J; WU D., ENHANCED ENDOCYTOSIS IN CULTURED HUMAN BREAST CARCINOMA CELLS AND IN VIVO BIODISTRIBUTION IN RATS OF A HUMANIZED MONOCLONAL ANTIBODY AFTER CATIONIZATION OF THE PROTEIN, (1998), vol. 286, no. L, pages 548 - 54
    - CHOTHIA ET AL., NATURE, (1989), vol. 342, page 877
    - SATO, K. ET AL., CANCER RES., (1993), vol. 53, pages 851 - 856
    - AMIT ET AL., SCIENCE, (1986), vol. 233, pages 747 - 53
    - CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 17
    - MOL IMMUNOL., (1999), vol. 36, no. 6, pages 387 - 395
    - ABHINANDAN K. R.; MARTIN C. R., J. MOL. BIOL., (2007), vol. 369, pages 852 - 862
    - CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 8
    - MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 97
    - WATERHOUSES ET AL., NUCLEIC ACIDS RES., (1993), vol. 21, pages 2265 - 6
    - GRIFFITHS ET AL., EMBO J., (1994), vol. 13, pages 3245 - 60
    - VAUGHAN ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 309 - 14
    - MENDEZ ET AL., NAT. GENET, (1997), vol. 15, pages 146 - 56
    - GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103
    - G. KOHLER; C. MILSTEIN, METHODS ENZYMOL., (1981), pages 3 - 46
    - K. SATO ET AL., CANCER RES., (1993), vol. 53, pages 851 - 856
    - KUNKEL, PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, page 488
    - BIOTECHNOL BIOENG., (2004), vol. 87, no. 5, pages 614 - 22
    - BIOTECHNOL BIOENG, (2006), vol. 93, no. 5, pages 851 - 61
    - NATURE BIOTECHNOLOGY, (2006), vol. 24, pages 1591 - 7
    - NATURE BIOTECHNOLOGY, (2006), vol. 24, pages 210 - 5
    - MOL. CELL BIOL., (1998), vol. 8, pages 466 - 472
    - J. EXP. MED., (1995), vol. 108, page 945
    - VALLE ET AL., NATURE, (1981), vol. 291, pages 338 - 340
    - EBERT ET AL., BIO/TECHNOLOGY, (1994), vol. 12, pages 699 - 702
    - SUSUMU ET AL., NATURE, (1985), vol. 315, pages 592 - 594
    - MA ET AL., EUR. J. IMMUNOL., (1994), vol. 24, pages 131 - 138
    - COX K.M. ET AL., NAT. BIOTECHNOL., (200612), vol. 24, no. 12, pages 1591 - 1597
    - CURR. OPIN. BIOTECHNOL, (199408), vol. 5, no. 4, pages 428 - 33
    - NAT. BIOTECHNOL., (200509), vol. 23, no. 9, pages L 126 - 36
    - CO, M. S. ET AL., J. IMMUNOL., (1994), vol. 152, pages 2968 - 2976
    - BETTER, M.; HORWITZ, A. H., METHODS IN ENZYMOLOGY, (1989), vol. 178, pages 476 - 496
    - PLIICKTHUN, A.; SKERRA, A., METHODS IN ENZYMOLOGY, (1989), vol. 178, pages 497 - 515
    - LAMOYI, E., METHODS IN ENZYMOLOGY, (1989), vol. 121, pages 652 - 663
    - ROUSSEAUX, J. ET AL., METHODS IN ENZYMOLOGY, (1989), vol. 121, pages 663 - 66
    - BIRD, R. E. ET AL., TIBTECH, (1991), vol. 9, pages 132 - 137
    - HUSTON, J. S. ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883
    - MOL. IMMUNOL, (199301), vol. 30, no. 1, pages 105 - 8
    - EUR. J. IMMUNOL., (199908), vol. 29, no. 8, pages 2613 - 24
    - HASHIMOTO-GOTOH, T.; MIZUNO, T.; OGASAHARA, Y.; NAKAGAWA, M., "An oligodeoxyribonucleotide-directed dual amber method for site-directed mutagenesis", GENE, (1995), vol. 152, doi:doi:10.1016/0378-1119(94)00750-M, pages 271 - 275, XP004042690

DOI:   http://dx.doi.org/10.1016/0378-1119(94)00750-M
    - ZOLLER, M. J.; SMITH, M., "Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors", METHODS ENZYMOL., (1983), vol. 100, doi:doi:10.1016/0076-6879(83)00074-9, pages 468 - 500, XP001088749

DOI:   http://dx.doi.org/10.1016/0076-6879(83)00074-9
    - KRAMER, W.; DRUTSA, V.; JANSEN, H. W.; KRAMER, B.; PFLUGFELDER, M.; FRITZ, H. J., "The gapped duplex DNA approach to oligonucleotide-directed mutation construction", NUCLEIC ACIDS RES., (1984), vol. 12, pages 9441 - 9456, XP002026371
    - KRAMER W.; FRITZ H. J., "Oligonucleotide-directed construction of mutations via gapped duplex DNA Methods", ENZYMOL, (1987), vol. 154, pages 350 - 367
    - KUNKEL, T. A., "Rapid and efficient site-specific mutagenesis without phenotypic selection", PROC. NATL. ACAD. SCI. USA, (1985), vol. 82, doi:doi:10.1073/pnas.82.2.488, pages 488 - 492, XP002052322

DOI:   http://dx.doi.org/10.1073/pnas.82.2.488
    - MOL. IMMUNOL., (200704), vol. 44, no. 11, pages 3049 - 60
    - NATURE BIOTECHNOLOGY, (2007), vol. 25, pages 563 - 565
    - NATURE BIOTECHNOLOGY, (1998), vol. 16, pages 773 - 777
    - BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1999), vol. 255, pages 444 - 450
    - NATURE BIOTECHNOLOGY, (2005), vol. 23, pages 1159 - 1169
    - JOURNAL OF VIROLOGY, (2001), vol. 75, pages 2803 - 2809
    - BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2003), vol. 308, pages 94 - 100
    - R. W. MALONE ET AL., PROC. NATL. ACAD. SCI. USA, (1989), vol. 86, page 6077
    - P. L. FEIGNER ET AL., PROC. NATL. ACAD. SCI. USA, (1987), vol. 84, page 7413
    - F. L. GRAHAM; A. J. VAN DER EB, VIROLOGY, (1973), vol. 52, pages 456 - 467
    - MOL. IMMUNOL., (199301), vol. 30, no. 1, pages 105 - 8
    - J. BIOCHEM., (1990), vol. 108, pages 673 - 676
    - YAMASAKI ET AL., SCIENCE, (1988), vol. 241, pages 825 - 828
    - HIBI ET AL., CELL, (1990), vol. 63, pages 1149 - 1157
    - HIRATA ET AL., FEBS LETTER, (1994), vol. 356, pages 244 - 248
    - CANCER RES., (19930215), vol. 53, no. 4, pages 851 - 6
    - J. MOL. BIOL., (1996), vol. 256, pages 77 - 88
    - NATURE BIOTECHNOLOGY, (199906), vol. 17, pages 568 - 572
    - J. IMMUNOLOGICAL METHODS, (1999), vol. 231, pages 119 - 135
    - NATURE BIOTECHNOLOGY, (200012), vol. 18, pages 1287 - 1292
    - JBC, (2004), vol. 279, no. 18, pages 18870 - 18877
    - J. MOL. BIOL., (1992), vol. 227, pages 381 - 388
    - METHODS, (200412), vol. 34, no. 4, pages 468 - 75
    - BIOCHEM. BIOPHYS. RES. COMMUN, (20070413), vol. 355, no. 3, pages 751 - 7
    - MOL IMMUNOL., (200704), vol. 44, no. 11, pages 3049 - 60
    - PROC. NATL. ACAD. SCI. USA., (19950523), vol. 92, no. 11, pages 4862 - 6
    - CHU GC, PHARM. RES., (20070324), vol. 24, no. 6, pages 1145 - 56
    - JOHNSON KA ET AL., ANAL. BIOCHEM., (20070101), vol. 360, no. 1, pages 75 - 83
    - CHU GC ET AL., PHARM RES., (20070324), vol. 24, no. 6, pages 1145 - 56
    - RODOLFO ET AL., IMMUNOLOGY LETTERS, (1999), pages 47 - 52
    - STRAND V ET AL., NAT. REV. DRUG DISCOV, (200701), vol. 6, no. 1, pages 75 - 92
    - GESSNER JE ET AL., ANN. HEMATOL, (199806), vol. 76, no. 6, pages 231 - 48
    - ANN. HEMATOL, (199806), vol. 76, no. 6, pages 231 - 48
    - COLE MS ET AL., J. IMMUNOL., (19971001), vol. 159, no. 7, pages 3613 - 21
    - REDDY MP ET AL., J. IMMUNOL., (20000215), vol. 164, no. 4, pages 1925 - 33
    - CHAU LA ET AL., TRANSPLANTATION, (20010415), vol. 71, no. 7, pages 941 - 50
    - KIM SJ ET AL., MOL CELLS, (20050831), vol. 20, no. 1, pages 17 - 29
    - J. IMMUNOL., (199908), vol. 29, no. 8, pages 2613 - 24
    - CANCER RESEARCH, (1993), vol. 53, pages 851 - 856
    - NAT. REV. IMMUNOL, (200709), vol. 7, no. 9, pages 715 - 25
    - NAT. BIOTECHNOL., (200712), vol. 25, no. 12, pages 1369 - 72
    - J. BIOL. CHEM., (20070119), vol. 282, no. 3, pages 1709 - 17
    - J. IMMUNOL., (20060101), vol. 176, no. 1, pages 346 - 56
    - PROC. NATL. ACAD. SCI. USA., (20061205), vol. 103, no. 49, pages 18709 - 14
    - INT. IMMUNOL, (200612), vol. 18, no. 12, pages 1759 - 69
    - J. EXP. MED., (1994), vol. 180, no. 6, pages 2377 - 2381
    - PROC. NATL. ACAD. SCI. USA., (2002), vol. 99, no. 26, pages 16899 - 16903
    - J. IMMUNOL., (20021101), vol. 169, no. 9, pages 5171 - 80
    - J. PHARM. SCI., (200804), vol. 97, no. 4, pages 1414 - 26
    - BIRNEY ET AL., ENSEMBL 2006, NUCLEIC ACIDS RES, (20060101), vol. 34, pages D556 - 61
    - YAGI T, PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 9918 - 22
    - POPO H, BIOCHEMICAL GENETICS, (1990), vol. 28, pages 299 - 308
    - WEITZHANDLER M. ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, (1994), vol. 83, no. 12, pages 1670 - 1675
    - SCHENK B ET AL., THE JOURNAL OF CLINICAL INVESTIGATION, (2001), vol. 108, no. 11, pages 1687 - 1695
    - BIGGE J. C. ET AL., ANALYTICAL BIOCHEMISTRY, (1995), vol. 230, no. 2, pages 229 - 238
    - PROTEIN SCIENCE, (1995), no. 4, pages 2411 - 2423
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.